🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Spain
Clinical trial register · European Union · CTIS

Clinical Trials in Spain

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
144 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms
2026-525484-40-00Post-Essential Thrombocythemia Myelofibrosis, Post-Polycyth…
Prelude Therapeutics Inc.
Neoplasms
Italy, France, Spain
27/07/2026
Phase I
Tarlatamab Before and After Surgery for Recurrent High-Grade Glioma
2025-524359-30-00surgically resectable recurrent high-grade glioma
Vall D Hebron Institute Of Oncology
Neoplasms
Spain
22/07/2026
Phase I
Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors
2025-523067-38-01Advanced Malignant Tumors; High-grade Serous Ovarian Carcin…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Spain, France, Italy
21/07/2026
Phase I
Study of MX006 in Patients With Advanced and/or Metastatic Tumors known to express B7-H3
2025-524929-41-00Advanced Solid Tumor Types Known to Express B7-H3
Myricx Pharma Limited
Neoplasms
Spain
20/07/2026
Phase I
Bioequivalence clinical trial of two formulations of dapagliflozin/metformin
2026-527164-32-00Healthy participants
Laboratorios Alter S.A.
Nutritional and Metabolic Diseases
Spain
17/07/2026
Phase I
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
2026-525234-39-00Relapsed or Refractory acute myeloid leukemia, Relapsed or …
Janssen Cilag International
Neoplasms
France, Spain, Germany, Denmark, Belgium
13/07/2026
Phase I
A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.
2026-525790-39-00Tuberculosis
Glaxosmithkline Research & Development Limited
Bacterial Infections and Mycoses
Spain
06/07/2026
Phase I
A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis
2025-523127-21-00Rheumatoid Arthritis
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
Belgium, Netherlands, Spain, Germany, Italy
01/07/2026
Phase I
A Phase 1 Randomized, Double-Blind, placebo-controlled, clinical study to evaluate safety and Pharmacokinetics, of Single Ascending Doses and Multiple Ascending Doses of AIK3a305 in Healthy Volunteers
2026-525830-49-00Treatment of several inflammatory diseases, including infla…
Allinky Biopharma S.L.
Not possible to specify
Spain
29/06/2026
Phase I
Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma
2025-525158-20-00Stage IIB/C, Stage III, or Stage IV Melanoma
Biocon Biologics UK PLC
Neoplasms
Spain, Romania
22/06/2026
Phase I
A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.
2026-525897-20-00High-risk non-muscle invasive bladder cancer (NMIBC)
Laboratorio Reig Jofre S.A.
Male Urogenital Diseases
Spain
18/06/2026
Phase I
Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer
2025-524687-38-00Other Solid Tumors Associated with Nectin-4 Expression, Rel…
Rondo Therapeutics Inc.
Neoplasms
Spain
17/06/2026
Phase I
Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer
2025-524690-16-00Solid Tumors
Theras Inc.
Neoplasms
Spain, Italy, France
16/06/2026
Phase I
A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation
2025-523648-11-00adenocarcinoma of the colon or rectum
Bayer Consumer Care AG
Neoplasms
Finland, Spain, Sweden, Italy, Denmark, Netherlands, Belgium
08/06/2026
Phase I
A study to test single and multiple doses of MER511 given to adults with Graves’ disease
2025-523823-23-00Graves’ disease
Merida Biosciences Inc.
Immune System Diseases
Spain
22/05/2026
Phase I
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors
2025-524165-25-00Neoplasms
Glaxosmithkline Research & Development Limited
Neoplasms
Spain, Denmark, Finland, France
21/05/2026
Phase I
A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors
2025-524192-24-00advanced refractory solid tumors
Samsung Bioepis Co. Ltd.
Neoplasms
Spain
18/05/2026
Phase I
A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)
2025-520631-17-00Huntington’s Disease Gene Expansion Carriers
F. Hoffmann-La Roche AG
Nervous System Diseases
Italy, Poland, Denmark, Germany, Portugal, Spain
11/05/2026
Phase I
First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors
2025-521173-13-00Advanced Solid Tumors
Daiichi Sankyo Inc.
Neoplasms
France, Spain
08/05/2026
Phase I
Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer
2025-522888-15-00Small Cell Lung Cancer
Amgen Inc.
Neoplasms
Spain, Germany, Poland, Belgium, France
05/05/2026
Phase I
CD5CAR-NK cells for refractory invasive mold disease
2025-524638-24-00refractory invasive mold disease
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Bacterial Infections and Mycoses
Spain
04/05/2026
Phase I
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors
2025-524857-15-00Advanced Solid Tumors
BeOne Medicines I GmbH
Neoplasms
Spain
30/04/2026
Phase I
Bioequivalence clinical trial of two formulations of canagliflozin
2026-525944-14-00Healthy volunteers
Laboratorios Normon S.A.
Not possible to specify
Spain
29/04/2026
Phase I
Bioequivalence clinical trial of two formulations of loperamide.
2026-525278-20-00Healthy volunteers
Laboratorios Normon S.A.
Not possible to specify
Spain
29/04/2026
Phase I
Pilot, randomized, crossover, comparative bioavailability study of two tadalafil formulations (oral suspension and film-coated tablets) after a single oral dose of 20 mg under fasting conditions in healthy male volunteers.
2026-525930-47-00Healthy volunteers
Farmalider S.A.
Not possible to specify
Spain
29/04/2026
Rows per page Showing 26–50 of 144
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe/country/spain

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.